Preferred Label : Linagliptin;

MeSH definition : A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.;

MeSH synonym : 1H-purine-2,6-dione, 8-((3r)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-; (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione;

MeSH hyponym : tradjenta; BI 1356; 1356, BI; BI1356; BI-1356; Trajenta;

MeSH Related Number : 668270-12-0;

Wikipedia link : https://en.wikipedia.org/wiki/Linagliptin;

Is substance : O;

UNII : 3X29ZEJ4R2;

Details


Main resources

You can consult :

A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.

https://www.has-sante.fr/jcms/p_3282770/fr/trajenta-linagliptine
2021
false
false
false
France
evaluation of the transparency committee
Linagliptin
treatment outcome
insurance, health, reimbursement
administration, oral
diabetes mellitus, type 2
dipeptidyl-peptidase iv inhibitors
Product containing precisely linagliptin 5 milligram/1 each conventional release oral tablet (clinical drug)
incretins
linagliptin
drug therapy, combination

---
https://www.has-sante.fr/jcms/p_3283458/fr/jentadueto-linagliptine/-metformine
2021
false
false
false
France
evaluation of the transparency committee
Metformin Hydrochloride
metformin
drug combinations
treatment outcome
insurance, health, reimbursement
diabetes mellitus, type 2
administration, oral
Linagliptin
metformin and linagliptin
hypoglycemic agents
dipeptidyl-peptidase iv inhibitors
Product containing only linagliptin and metformin in oral dose form (medicinal product form)
incretins
jentadueto

---
https://www.ema.europa.eu/medicines/human/EPAR/Glyxambi
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
Linagliptin
empagliflozin
drug approval
europe
treatment outcome
pregnancy
breast feeding
hypoglycemic agents
hypoglycemic agents
adult
diabetes mellitus, type 2
product surveillance, postmarketing
linagliptin and empagliflozin
administration, oral
Sodium-Glucose transporter 2
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
drug evaluation, preclinical
Product containing empagliflozin and linagliptin (medicinal product)
Sodium-Glucose Transporter 2 Inhibitors
Linagliptin
empagliflozin
benzhydryl compounds
glucosides
benzhydryl compounds
glucosides

---
https://www.revmed.ch/RMS/2016/RMS-N-527/Combinaison-gliptine-gliflozine-dans-le-traitement-du-diabete-de-type-2
2016
false
false
false
Switzerland
French
journal article
diabetes mellitus, type 2
drug combinations
hypoglycemic agents
dipeptidyl-peptidase iv inhibitors
SGLT2 Inhibitor
treatment outcome
saxagliptin and dapagliflozin
dapagliflozin
saxagliptin
Linagliptin
linagliptin and empagliflozin
empagliflozin
Product containing empagliflozin and linagliptin (medicinal product)
administration, oral
Sodium-Glucose transporter 2
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
dipeptides
adamantane
adamantane
benzhydryl compounds
glucosides

---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/trajenta-2329.html
2013
false
Canada
English
French
drug evaluation
Linagliptin
evaluation of the transparency committee
diabetes mellitus, type 2
administration, oral
dipeptidyl-peptidase iv inhibitors
linagliptin
hypoglycemic agents
adult
drug therapy, combination
treatment outcome
Cost-Benefit analysis
Glycated Hemoglobin
Product containing glucagon-like peptide 1 receptor agonist (product)
Substance with glucagon-like peptide 1 receptor agonist mechanism of action (substance)

---
http://www.has-sante.fr/portail/jcms/c_1615041/fr/trajenta
http://www.has-sante.fr/portail/jcms/c_1615040/fr/trajenta-20032013-avis-ct12642
2013
false
France
French
Linagliptin
Linagliptin
Product containing precisely linagliptin 5 milligram/1 each conventional release oral tablet (clinical drug)
evaluation of the transparency committee
linagliptin
administration, oral
insurance, health, reimbursement
treatment outcome
drug therapy, combination
metformin
insulin
hypoglycemic agents
dipeptidyl-peptidase iv inhibitors
diabetes mellitus, type 2
dipeptidyl-peptidase iv inhibitors

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-07/trajenta_20062012_avis_ct11905.pdf
http://www.has-sante.fr/portail/jcms/c_1277891/trajenta
2012
false
France
French
evaluation of the transparency committee
Linagliptin
Linagliptin
Product containing precisely linagliptin 5 milligram/1 each conventional release oral tablet (clinical drug)
linagliptin
insurance, health, reimbursement
administration, oral
diabetes mellitus, type 2
adult
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
drug therapy, combination
treatment outcome
clinical trials, phase iii as topic
randomized controlled trials as topic
aged
renal insufficiency

---
https://www.ema.europa.eu/medicines/human/EPAR/Jentadueto
2012
false
United Kingdom
French
English
summary of product characteristics
package leaflet
drug evaluation
syndication feed
Linagliptin
Linagliptin
Product containing linagliptin and metformin in oral dose form (medicinal product form)
aged
drug interactions
pregnancy
fertility
breast feeding
controlled clinical trials as topic
drug evaluation, preclinical
metformin
metformin
drug combinations
metformin and linagliptin
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
hypoglycemic agents
hypoglycemic agents
drug approval
treatment outcome
administration, oral
diabetes mellitus, type 2
adult
drug therapy, combination

---
http://www.has-sante.fr/portail/jcms/c_1296077/trajenta-synthese-20062012
http://www.has-sante.fr/portail/jcms/c_1296078/trajenta-linagliptine-inhibiteur-de-la-dipeptidylpeptidase-4
http://www.has-sante.fr/portail/jcms/c_1278227/trajenta-20062012-avis-ct11905
2012
false
France
French
Linagliptin
Linagliptin
Product containing precisely linagliptin 5 milligram/1 each conventional release oral tablet (clinical drug)
linagliptin
administration, oral
adult
aged
clinical trials as topic
diabetes mellitus, type 2
drug therapy, combination
Glycated Hemoglobin
insurance, health, reimbursement
treatment outcome
renal insufficiency
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
guidelines for drug use
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_1298544/jentadueto
http://www.has-sante.fr/portail/jcms/c_1298694/jentadueto-05092012-avis-ct12491
2012
false
France
French
Linagliptin
Linagliptin
Product containing linagliptin and metformin in oral dose form (medicinal product form)
metformin and linagliptin
administration, oral
adult
aged
diabetes mellitus, type 2
drug combinations
drug therapy, combination
Glycated Hemoglobin
hypoglycemic agents
hypoglycemic agents
insurance, health, reimbursement
metformin
metformin
treatment outcome
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
evaluation of the transparency committee

---
https://www.ema.europa.eu/medicines/human/EPAR/Trajenta
2012
false
United Kingdom
English
French
drug evaluation
summary of product characteristics
package leaflet
syndication feed
Linagliptin
Linagliptin
Product containing precisely linagliptin 5 milligram/1 each conventional release oral tablet (clinical drug)
pregnancy
breast feeding
drug evaluation, preclinical
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
linagliptin
administration, oral
diabetes mellitus, type 2
drug therapy, combination
drug approval
treatment outcome
drug interactions

---
Nous contacter.
04/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.